Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
South Korea flag South Korea · Delayed Price · Currency is KRW
87,100
+2,800 (3.32%)
Apr 10, 2026, 3:30 PM KST

Mezzion Pharma Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
7,9108,61231,72130,72626,654
Other Revenue
---0--
7,9108,61231,72130,72626,654
Revenue Growth (YoY)
-8.15%-72.85%3.24%15.28%-6.92%
Cost of Revenue
6,5296,70127,83631,04022,956
Gross Profit
1,3811,9103,884-313.443,698
Selling, General & Admin
15,97314,95816,14219,51017,283
Research & Development
1,260294.04938.972,2171,956
Operating Expenses
18,22116,21018,37323,01820,496
Operating Income
-16,840-14,300-14,489-23,331-16,798
Interest Expense
-1,572-300.79-315.46-423.44-323.41
Interest & Investment Income
621.961,4311,477763.35306.23
Currency Exchange Gain (Loss)
-71.67286.56996.943,1773,700
Other Non Operating Income (Expenses)
-21,020-1,180-157.21-1,41090.67
EBT Excluding Unusual Items
-38,882-14,062-12,488-21,225-13,025
Gain (Loss) on Sale of Assets
44.05-471.697.358.99-1.08
Asset Writedown
----14,694-
Pretax Income
-38,838-14,534-12,480-35,910-13,026
Income Tax Expense
-3,9094,943248.07388.23577.06
Earnings From Continuing Operations
-34,929-19,477-12,728-36,298-13,603
Net Income
-34,929-19,477-12,728-36,298-13,603
Net Income to Common
-34,929-19,477-12,728-36,298-13,603
Shares Outstanding (Basic)
3030282727
Shares Outstanding (Diluted)
3030282727
Shares Change (YoY)
0.95%5.62%5.63%0.17%2.63%
EPS (Basic)
-1160.00-653.00-450.74-1357.81-509.70
EPS (Diluted)
-1160.00-653.00-451.00-1358.00-510.00
Free Cash Flow
-16,725-19,080-11,553-12,842-15,429
Free Cash Flow Per Share
-555.46-639.69-409.10-480.39-578.14
Gross Margin
17.46%22.18%12.25%-1.02%13.88%
Operating Margin
-212.91%-166.05%-45.67%-75.93%-63.02%
Profit Margin
-441.61%-226.17%-40.13%-118.13%-51.03%
Free Cash Flow Margin
-211.46%-221.56%-36.42%-41.80%-57.89%
EBITDA
-15,852-13,342-12,942-21,673-15,212
EBITDA Margin
-200.42%-154.93%-40.80%-70.54%-57.07%
D&A For EBITDA
988.12957.81,5461,6581,586
EBIT
-16,840-14,300-14,489-23,331-16,798
EBIT Margin
-212.91%-166.05%-45.67%-75.93%-63.02%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.